SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community debates potential golden cross formations and key support levels. Bullish investors are actively defending against bears, citing Litecoin's history and potential for significant gains, while some compare its chart to Nvidia's. Discussions also include Litecoin's utility for real-world payments and potential integrations.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss its potential market cap adjustment as it approaches Phase 3 trials, drawing comparisons to Madrigal Pharmaceuticals. Community members are actively debating the possibility of a buyout, upcoming news catalysts, and management's strategy. Bullish sentiment is fueled by the drug's potential in treating MASH and obesity.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending due to its strong meme culture and active community involvement within the $SOL ecosystem. Community members emphasize the coin's organic growth and the 'infectious' nature of its community, suggesting it's poised for significant upward movement. The coin's association with meme culture and community engagement appears to be a key driver of its current popularity.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending as the community speculates on potential price movements and compares it to other meme coins. Some traders are highlighting support levels and anticipating a significant price surge, while others discuss the coin's long-term potential and developments within its ecosystem. Comparisons to other meme coins like $BONK and $SAILANA are fueling the conversation.

Moo Deng

Moo Deng is trending with community members pointing to a recent surge, with some comparing it to HKD's 2021 run, while others believe it's a pump and dump. The community is actively discussing potential price movements, debating whether it will reach previous highs or fall further, and anticipating another pump. Discussion includes positive and negative sentiment as some traders express frustration with its performance while others remain optimistic about potential gains.

CryingNTheCasino

TEARY CRYPTO is gaining attention as a Solana-based token drawing comparisons to early BONK, with the community emphasizing its strong, active engagement and the project's ethos of resilience. The "No Crying In The Casino" mantra resonates as users express patience and confidence in the coin's potential, highlighting the value of community-driven initiatives within the crypto space.

Verb Ai

Verb Ai ($VERB) is trending alongside other stocks like Ford and OXBR, with community members highlighting potential connections and past successes. The community is actively discussing the stock's potential and its relationship to other trending symbols, particularly $OXBR.

The DEADBOX ecosystem coin DEAD introduces "Grave Digging" — a mechanism allowing active holders of >1,000,000 DEAD tokens to claim any inactive DEAD tokens out of holders wallet after 90 days of inactivity!  50% is kept by the Grave Digger 40% is burnt forever - making all holders richer! 10% is sent to DEADBOX Treasury for the R&D of new rev-share products.  DEAD tokens are also the primary token in the Dead Token Economy and can be burnt to create our utility token UNDEAD - making tokens immune from falling victim to Grave Digging. UNDEAD tokens also are distributed a dividend share of the ecosystem's revenues and rewards automatically into holders wallets in realtime - no staking required.

DEAD

$DEAD is gaining attention as meme season ramps up, with the community drawing comparisons to other meme coins. Traders are actively discussing its potential and highlighting it alongside other tokens.

Terra 2.0 which will assume the Terra name is a new blockchain launched by Terraform Labs as part of the passing of governance proposal 1623.  The Terra protocol is a decentralized and open-source public blockchain protocol. Luna is the Terra protocol’s native staking token used for governance and mining.  Users stake Luna to validators who record and verify transactions on the blockchain in exchange for rewards from transaction fees.  The Terra 2.0 chain will not have a stablecoin and holders of the old Terra Classic chain will be airdropped new Luna native coins. In the plan, developers of the Terra ecosystem are to migrate and deploy their dapps on the new blockchain.

Terra 2.0

Terra 2.0 ($LUNA) is trending amid discussions about potential ecosystem developments and community speculation regarding price predictions. Some traders are moving profits from LUNC to LUNA, while others are wary of a potential pump and dump, remembering past volatility. Community members are also discussing ongoing legal situations with Do Kwon.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

Sui (SUI) is seeing increased community interest, potentially fueled by news of the first Sui-based ETF being approved and the addition of a veteran from EA Sports to the Sui Foundation. Community members are comparing SUI to early Solana, noting its potential for growth, while others discuss its high transaction speeds and the launch of a new stablecoin, USDsui. Some traders suggest that SUI is oversold and undervalued, presenting a buying opportunity despite concerns about token unlocks and dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT

Geode Capital Management LLC lifted its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 13.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission...

Altimmune (NASDAQ:ALT) Stock Price Down 6.6% - Time to Sell?

Altimmune (NASDAQ:ALT) Shares Down 6.6% - Here's What Happened...

Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT

Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...

Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...

Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

<ul class="summary-bullets"><li>Retail traders focused on AI-driven biopsy findings and clearer dose-response&nbsp;exuded increased confidence in pemvidutide’s potential.</li><li>Analysts remained divided, with&nbsp;some citing strong MASH resolution and safety, while skeptics questioned differentiation and funding needs.</li><li>Lancet publication and AASLD late-breaker added momentum as Altimmune advanced additional liver-disease programs toward 2026 readouts.</li></ul><p>Retail discussion around Altimmune intensified over the weekend as investors looked ahead to the 48-week readout from the company’s IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2025.&nbsp;</p><h2 class="st-heading-2"><strong>AI-Based Biopsy Analysis Adds Fresh Momentum</strong></h2><p>Last week, Altimmune released results from an AI-based analysis of liver biopsies from the IMPACT Phase 2b trial. The company reported that 31% of patients in the 1.8 mg pemvidutide arm and 12% in the 1.2 mg arm achieved a 60% reduction in total fibrosis, compared with 8% for placebo. Improvements were also observed in early and advanced fibrosis categories, with reductions in the area of fibrosis exceeding 60% in select patient groups compared with placebo.</p><p>Following the analysis, Citizens JMP lowered its price target to $14 and maintained an ‘Outperform’ rating,&nbsp;noting that&nbsp;it looked ahead to the late-breaking oral presentation at the Liver Meeting and the 48-week dataset expected this quarter. UBS maintained a ‘Buy’ rating, while Jefferies reiterated its ‘Buy’ recommendation, viewing pemvidutide as viable after meeting key histology endpoints at 24 weeks.</p><h2 class="st-heading-2"><strong>Mixed MASH Readout In July Still Shapes Sentiment</strong></h2><p>Altimmune’s June and July update on its 24-week IMPACT&nbsp;Phase 2b results set the tone for the stock this year.&nbsp;The company reported that up to 59.1% of patients on pemvidutide achieved MASH resolution without worsening of fibrosis, compared to 19.1% for the placebo group. However, the endpoint of fibrosis improvement without worsening of MASH did not reach statistical significance.</p><p>Despite this, the trial showed reductions in liver fat, inflammation and biomarkers of fibrosis, alongside meaningful weight loss, with up to 6.2% loss in treated patients compared with 1.0% for placebo. Safety remained favorable, with extremely low discontinuations and no drug-related serious adverse events.</p><h2 class="st-heading-2"><strong>Analyst Community Diverges Across The Year</strong></h2><p>Bullish analysts’ optimism hinged on the drug’s early MASH resolution signal, weight loss trajectory and tolerability. UBS, Stifel, Jefferies and H.C. Wainwright all maintained ‘Buy’ ratings at various points, describing the 24-week results as either differentiated, fast-acting, viable for Phase 3 advancement or supportive of a potential best-in-class profile. Several of these firms highlighted AI-assisted fibrosis reads and non-invasive tests as consistent with anti-fibrotic activity.</p><p>Others expressed more skepticism. In October, Citizens JMP cut its target earlier, while still keeping an ‘Outperform’ rating. Goldman Sachs resumed coverage with a ‘Sell’ rating, citing a lack of meaningful differentiation in obesity and MASH. Concerns about the company’s ability to fund a full Phase 3 program, especially after the mixed fibrosis outcome, were noted among analysts.</p><h2 class="st-heading-2"><strong>Peer-Reviewed Boost</strong></h2><p>Last week, Altimmune said that The Lancet had published the 24-week efficacy and safety data from the IMPACT Phase 2b trial. The data were also selected for a late-breaking oral presentation at The Liver Meeting 2025 hosted by AASLD. Investigators highlighted significant MASH resolution, reductions in liver fat, anti-fibrotic signals and weight loss, reinforcing the drug’s potential to treat patients with moderate to advanced fibrosis.</p><h2 class="st-heading-2"><strong>Stocktwits Users See No ‘Breaks’ Ahead</strong></h2><p>On Stocktwits, retail sentiment for Altimmune was ‘bullish’ amid ‘high’ message volume.</p><figure class="image"><img style="aspect-ratio:972/139;" src="https://news.stocktwits-cdn.com/alt_ss_jpg_da81507313.webp" alt="alt ss.jpg" width="972" height="139"><figcaption>ALT sentiment and message volume as of November 16 | Source: Stocktwits</figcaption></figure><p>One user discussing the upcoming 48-week dataset pointed to the latest AASLD-published fibrosis odds-ratio findings and the clearer dose-response signals seen in the PathAI-derived analysis, suggesting these results strengthen the case for exploring a higher 2.4 mg dose aimed at accelerating fibrosis reduction, while keeping 1.8 mg and 1.2 mg positioned for broader cardiometabolic use and long-term maintenance.</p><p><stembedurl>https://stocktwits.com/BTECHINV/message/636410473</stembedurl></p><p>Another user said, “If 48 week MASH data is ‘BEST IN CLASS’ like the weight loss/muscle sparring data, we should get at least $15B for both…not to mention the other indications.”</p><p><stembedurl>https://stocktwits.com/Lazarus2024/message/636408646</stembedurl></p><p>A third user said, “48 week should confirm fibrosis improvement and we should race to 2 billion MC on it FAST. no breaks once it’s out.”</p><p><stembedurl>https://stocktwits.com/SuperPuncher/message/636408207</stembedurl></p><p><a href="https://stocktwits.com/symbol/ALT">Altimmune’s stock</a> has declined 42% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Equity

FY2025 EPS Estimates for Altimmune Boosted by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Altimmune in a research note issued to investors on Tuesday...

Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALT News

ALTAltimmune Inc